Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Meeting Abstract
| Authors: | Robert, C.; Ribas, A.; Hamid, O.; Daud, A.; Wolchok, J. D.; Joshua, A. M.; Hwu, W. J.; Weber, J. S.; Gangadhar, T. C.; Joseph, R. W.; Dronca, R. S.; Patnaik, A.; Zarour, H. M.; Kefford, R.; Hersey, P.; Li, X. Y.; Diede, S. J.; Ebbinghaus, S.; Hodi, F. S. |
| Abstract Title: | Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 484s |
| Language: | English |
| ACCESSION: | WOS:000404711507125 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.9503 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9503 -- Source: Wos |
